[1]李书华.倍他司汀治疗原发性HC-BPPV患者复位后残余头晕的效果[J].医学信息,2022,35(01):158-161.[doi:10.3969/j.issn.1006-1959.2022.01.039]
　LI Shu-hua.Effect of Betahistine on Residual Dizziness After Reduction in Patients with Primary HC-BPPV[J].Medical Information,2022,35(01):158-161.[doi:10.3969/j.issn.1006-1959.2022.01.039]
点击复制

倍他司汀治疗原发性HC-BPPV患者复位后残余头晕的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年01期
页码:
158-161
栏目:
药物与临床
出版日期:
2022-01-01

文章信息/Info

Title:
Effect of Betahistine on Residual Dizziness After Reduction in Patients with Primary HC-BPPV
文章编号:
1006-1959（2022）01-0158-04
作者:
李书华
（无锡市第二中医院脑病科，江苏 无锡 214100）
Author(s):
LI Shu-hua
(Department of Encephalopathy,Wuxi Second Hospital of Traditional Chinese Medicine,Wuxi 214100, Jiangsu,China)
关键词:
良性阵发性位置性眩晕; 倍他司汀; 手法复位; 残余头晕
Keywords:
Benign paroxysmal positional vertigo; Betahistine; Manual reduction; Residual dizziness
分类号:
R764
DOI:
10.3969/j.issn.1006-1959.2022.01.039
文献标志码:
A
摘要:
目的 研究倍他司汀治疗原发性水平半规管良性阵发性位置性眩晕（HC-BPPV）患者复位后残余头晕的效果。方法 选择2019年10月-2020年10月本院收治的HC-BPPV复位后残余头晕的患者76例作为研究对象，使用随机数表字法将其分为观察组和对照组，每组38例。对照组使用手法复位进行治疗，观察组在对照组基础上联合使用盐酸倍他司汀治疗，比较两组治疗前后眩晕障碍量表（DHI）、抑郁自评量表（SDS）、焦虑自评量表（SAS）评分、纤维蛋白原（FIB）、全血高切黏度、血浆粘度水平、眼性及颈性前庭诱发肌源性动作电位（VEMP）异常情况及HC-BPPV复发情况。结果 观察组DHI、SDS、SAS评分低于对照组，差异有统计学意义（P＜0.05）；观察组FIB、血浆粘度、全血高切黏度水平低于对照组，差异有统计学意义（P＜0.05）；观察组治疗后2、4周眼性、颈性VEMP异常发生率低于对照组，差异有统计学意义（P＜0.05）；两组治疗后2、4、6个月HC-BPPV复发率比较，差异无统计学意义（P＞0.05）。结论 倍他司汀治疗原发性HC-BPPV患者复位后残余头晕可减轻患者眩晕症状，改善抑郁、焦虑等不良情绪，减少VEMP异常情况，且复发率低。
Abstract:
Objective To study the effect of betahistine in the treatment of residual dizziness after reduction in patients with primary semicircular canal benign paroxysmal positional vertigo (HC-BPPV).Methods A total of 76 patients with residual dizziness after HC-BPPV reduction admitted to our hospital from October 2019 to October 2020 were selected as subjects. They were divided into observation group and control group by random number table method, with 38 cases in each group. The control group was treated with manual reduction, and the observation group was treated with betahistine hydrochloride on the basis of the control group. The vertigo disorder scale (DHI), self-rating depression scale (SDS), self-rating anxiety scale (SAS) score, fibrinogen (FIB), whole blood high shear viscosity, plasma viscosity level, ocular and cervical vestibular evoked myogenic action potential (VEMP) abnormalities and HC-BPPV recurrence were compared between the two groups before and after treatment.Results The scores of DHI, SDS and SAS in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). FIB, plasma viscosity and whole blood high shear viscosity in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). The incidence of abnormal ocular and cervical VEMP in the observation group was lower than that in the control group at 2 and 4 weeks after treatment, and the difference was statistically significant (P<0.05). There was no significant difference in the recurrence rate of HC-BPPV between the two groups at 2, 4 and 6 months after treatment (P>0.05).Conclusion Residual dizziness after reduction in patients with primary HC-BPPV treated with betahistine can reduce vertigo symptoms, improve depression, anxiety and other adverse emotions, reduce VEMP abnormalities, and the recurrence rate is low.

参考文献/References:

[1]黄小段,钟翠萍.高原地区伴良性阵发性位置性眩晕的突发性耳聋的临床特点[J].海南医学,2017,28(19):3160-3162.[2]Das S,Rea PA.Bilateral posterior semi‐circular canal obliteration surgery for refractory benign paroxysmal positional vertigo (BPPV) in three patients[J].Clinical Otolaryngology,2017,42(2):480-483.[3]Kim SY,Han SH,Kim YH,et al.Clinical features of recurrence and osteoporotic changes in benign paroxysmal positional vertigo[J].Auris Nasus Larynx,2017,44(2):156-161.[4]马晓依,王月,肖钰雪.茯苓饮加减治疗良性阵发性位置性眩晕手法复位后残余头晕[J].吉林中医药,2019,39(10):1301-1303,1309.[5]Bhattacharyya N,Gubbels SP,Schwartz SR,et al.Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update) Executive Summary[J].Otolaryngology Head and Neck Surgery,2017,156(3):403-416.[6]王建洪,胡珍,高思敏,等.仪器辅助复位结合心理辅导治疗良性阵发性位置性眩晕[J].中国中西医结合耳鼻咽喉科杂志,2017,25(5):345-348.[7]李佩云,李春芳,孙力.高压氧疗法对颅脑损伤患者BI指数、GCS、SAS、SDS的影响[J].海南医学院学报,2017,23(16):2289-2291,2295.[8]Isik GC,Cevik Y,Emektar E,et al.Analysis of Vitamin D and Calcium Levels in Benign Paroxysmal Positional Vertigo[J].Eurasian Journal of Emergency Medicine,2017,16(3):128-132.[9]Choi SY,Oh SW,Kim HJ,et al.Determinants for bedside lateralization of benign paroxysmal positional vertigo involving the horizontal semicircular canal[J].Journal of Neurology,2020,267(6):1709-1714.[10]Novoa I,Urrutia C,Donoso SI,et al.Residual dizziness, a frequent clinical condition following successful repositioning maneuver for benign paroxysmal positional vertigo: A review[J].Revista de Otorrinolaringología y Cirugía de Cabeza y Cuello,2020,80(2):201-208.[11]谢涛,黄流清.倍他司汀联合利多卡因治疗良性阵发性位置性眩晕患者管石复位后残余头晕的疗效[J].中国新药与临床杂志,2019,38(3):165-169.[12]Kaur J,Shamanna K.Management of Benign Paroxysmal Positional Vertigo: A Comparative Study between Epleys Manouvre and Betahistine[J].Int Tinnitus J,2017,21(1):30-34.[13]Scholtz AW,Hahn A,Stefflova B,et al.Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial[J].Clin Drug Investig,2019,39(11):1045-1056. [14]Wu P,Cao W,Hu Y,et al.Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial[J].BMJ Open,2019,9(6):e026711.[15]Hegemann S,Christian W,Arneborg E,et al.Constant severe imbalance following traumatic otoconial loss: a new explanation of residual dizziness[J]. Eur Arch Otorhinolaryngol,2020,277(3):1-9.[16]Ballvé JL,Carrillo-Munoz R,Rando-Matos Y,et al.Effectiveness of the Epley manoeuvre in posterior canal benign paroxysmal positional vertigo: a randomised clinical trial in primary care[J].Br J Gen Pract,2019,69(678):e52-e60. [17]Sanchez-Vanegas G,Castro-Moreno C,Buitrago D.Betahistine in the Treatment of Peripheral Vestibular Vertigo: Results of a Real-Life Study in Primary Care[J].Ear Nose Throat J,2020,99(6):356-360. [18]Sayin I,Koc RH,Temirbekov D,et al.Betahistine add-on therapy for treatment of subjects with posterior benign paroxysmal positional vertigo: a randomized controlled trial[J].Braz J Otorhinolaryngol,2020:S1808-8694(20)30141-5.[19]王志平,张义,白秀清,等.改良手法复位与盐酸倍他司汀对BPPV患者临床治疗效果分析[J].基因组学与应用生物学,2018,37(11):5037-5042.[20]王冰,李玮,李六一,等.低频经颅磁刺激治疗阵发性位置性眩晕患者成功手法复位后残余头晕的疗效观察[J].中华物理医学与康复杂志,2017,39(4):286-289.[21]刘大为,夏菲,任媛媛.倍他司汀联合利多卡因对良性阵发性位置性眩晕患者管石复位治疗成功后残余头晕的疗效[J].临床和实验医学杂志,2020,19(13):1390-1394.[22]Oya R,Imai T,Takenaka Y,et al.Clinical significance of cervical and ocular vestibular evoked myogenic potentials in benign paroxysmal positional vertigo: a meta-analysis[J].Eur Arch Otorhinolaryngol,2019,276(12):3257-3265.[23]吴沛霞,刘建平,王武庆,等.良性阵发性位置性眩晕患者复位后残余症状的干预策略:单中心随机对照试验[J].中华耳鼻咽喉头颈外科杂志,2021,56(1):41-46.[24]Ozdemir D, Akpinar CK, Kücükoner O,et al.Vestibular evoked myogenic potential (VEMP) results in migraine and migrainous vertigo[J].Acta Otolaryngol,2020,140(2):140-143. [25]Lamounier P,de Souza TSA,Gobbo DA,et al.Evaluation of vestibular evoked myogenic potentials (VEMP) and electrocochleography for the diagnosis of Ménière’s disease[J].Braz J Otorhinolaryngol,2017,83(4):394-403.[26]Murofushi T,Tsubota M,Suzuki D.Idiopathic acute high-tone sensorineural hearing loss accompanied by vertigo: vestibulo-cochlear artery syndrome? Consideration based on VEMP and vHIT[J]. J Neurol,2019,266(8):2066-2067.

相似文献/References:

[1]吴达文,郭雪平,谢丽媛.天麻钩藤饮加减治疗肝阳上亢型后循环缺血性眩晕的效果[J].医学信息,2022,35(17):148.[doi:10.3969/j.issn.1006-1959.2022.17.041]
　WU Da-wen,GUO Xue-ping,XIE Li-yuan.Effect of Tianma Gouteng Decoction in the treatment of Posterior Circulation Ischemic Vertigo of Liver-yang Hyperactivity Type[J].Medical Information,2022,35(01):148.[doi:10.3969/j.issn.1006-1959.2022.17.041]
[2]邵垭杰,毕小江,孙心悦,等.倍他司汀联合盐酸氟桂利嗪治疗耳鸣的Meta分析[J].医学信息,2021,34(04):119.[doi:10.3969/j.issn.1006-1959.2021.04.031]
　SHAO Ya-jie,BI Xiao-jiang,SUN Xin-yue,et al.Meta Analysis of Betahistine Combined with Flunarizine Hydrochloride in the Treatment of Tinnitus[J].Medical Information,2021,34(01):119.[doi:10.3969/j.issn.1006-1959.2021.04.031]
[3]俞 越,任 静,文荟媛,等.阿普唑仑治疗BPPV患者复位后睡眠及情绪障碍的疗效[J].医学信息,2019,32(24):40.[doi:10.3969/j.issn.1006-1959.2019.24.013]
　YU Yue,REN Jing,WEN Hui-yuan,et al.The Efficacy of Alprazolam in the Treatment of Sleep and Mood Disorders in Patients with BPPV after Reduction[J].Medical Information,2019,32(01):40.[doi:10.3969/j.issn.1006-1959.2019.24.013]
[4]杨俊影,徐鹏程,张 群,等.基于SRM-Ⅳ型眩晕诊疗系统的BPPV患者临床特征分析[J].医学信息,2021,34(23):73.[doi:10.3969/j.issn.1006-1959.2021.23.020]
　YANG Jun-ying,XU Peng-cheng,ZHANG Qun,et al.Clinical Characteristics of BPPV Patients Based on SRM-Ⅳ Vertigo Diagnosis and Treatment System[J].Medical Information,2021,34(01):73.[doi:10.3969/j.issn.1006-1959.2021.23.020]
[5]何颖颖,陈雪生,沈崇岭.倍他司汀联合Epley手法复位对耳石症患者眩晕障碍及前庭症状的影响[J].医学信息,2023,36(13):127.[doi:10.3969/j.issn.1006-1959.2023.13.026]
　HE Ying-ying,CHEN Xue-sheng,SHEN Chong-ling.Effect of Betahistine Combined with Epley Manual Reduction on Vertigo Disorder and Vestibular Symptoms in Patients with Otolith[J].Medical Information,2023,36(01):127.[doi:10.3969/j.issn.1006-1959.2023.13.026]

更新日期/Last Update: 1900-01-01